<DOC>
	<DOC>NCT02145572</DOC>
	<brief_summary>The purpose of this study is to identify unique metabolite signatures associated with the development of Type 2 diabetes and diabetic kidney disease in children. We have a sub-study, with the purpose to validate the presence of a genetic marker (DENND1A) in the urine of adolescent females with polycystic ovarian syndrome.</brief_summary>
	<brief_title>Metabolomic Profiling in Adolescents With Obesity and Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>Age of 1319 years Gender: male and female Ethnic background: any Obesity will be defined as BMI &gt;95th percentile for age/gender Diagnosis of diabetes will be defined by current American Diabetes Association criteria Diabetes duration &lt; 2.5 years Absence of pancreatic autoimmunity (GAD65 and ICA512 and Insulin autoantibody) Adult caregiver willing to actively support study participation Signed parental informed consent form and adolescent assent form For PCOS substudy, the diagnosis of PCOS will be defined according to the 1990 US National Institute of Health (NIH) criteria (oligomenorrhea, clinical or biochemical signs of hyperandrogenism, and exclusion of other known disorders) Creatinine clearance &lt;60 mL/min (calculated from estimated GFR) Other significant organ system illness or condition (including psychiatric or developmental disorder) that, in the opinion of the investigator, would prevent participation. For PCOS substudy, use of medications that effect androgen levels in the blood (i.e. oral contraceptive pills, or metformin) for the last 3 months prior to enrollment</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>